Boston launches Taxus Element in Europe
This article was originally published in Clinica
Executive Summary
Boston Scientific has launched its third-generation drug-eluting stent, Taxus Element, in the EU and other countries that recognise the CE mark. Boston CE marked the paclitaxel-eluting device for use in patients including those with diabetes, last month (www.clinica.co.uk, 14 May 2010). The firm CE marked its Promus Element everolimus-eluting stent, which uses the same platinum chromium alloy and strut design as Taxus Element, in October 2009. Boston expects US FDA approval for Taxus Element in mid-2011, and for Promus Element a year later. Japanese approval for Taxus Element is slated for late 2011 or early 2012, and for Promus Element in mid-2012.